16179results about "Animals/human peptides" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Provided are a small-molecule antibacterial polypeptide, and a preparation method therefor and a use thereof. The antibacterial peptide provided has stronger antibacterial activity than most other derivative polypeptides and antibacterial polypeptides disclosed in existing reports. Multiple strains known for drug resistance are used to carry out bactericidal activity evaluation. The result shows that the antibacterial peptide provided has broad-spectrum antibacterial activity against drug-resistant strains, achieves more comprehensive antibacterial effects, and has a wider range of indications.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance the drought-tolerance of the cotton plant. By selectively choosing specific weights of feathers and water, and treating the mixture, though one embodiment does not have water mixed in, to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then applied to the cotton seeds and the soil around the cotton plants. Optionally, the KHP solution can be diluted by water, as taught in the specification, before applying to the seeds and the soil as taught herein.

Compositions of retroviruses and methods of using the same for gene delivery are disclosed, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications of sugars, nucleobases, and / or internucleotidic linkages and patterns thereof and are useful for exon skipping. In some embodiments, the present disclosure provides technologies useful for skipping exon 44 of dystrophin (DMD) transcripts. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, the present disclosure provides methods for preventing or treating conditions, disorders or diseases including Duchenne muscular dystrophy.

The present disclosure relates to the technical field of antibacterial drugs, and specifically relates to a micromolecular antibacterial polypeptide, and a preparation method therefor and the use thereof. The antibacterial peptide provided in the present disclosure has a stronger antibacterial activity compared with most other derived polypeptides and the antibacterial polypeptides disclosed in the existing reports. Bactericidal activity evaluation is carried out by using a plurality of strains known to have drug resistance, and the results show that the antibacterial peptide provided in the present disclosure has broad-spectrum antibacterial activity against drug-resistant strains and more comprehensive antibacterial effects, and allows for wider indications.

According to the brown planthopper lethal gene Nlpfam and the application thereof in biological prevention and control, the brown planthopper lethal gene Nlpfam can cause brown planthopper death after being interfered, so that dsRNA or an interference reagent is prepared through transcription of the brown planthopper lethal gene Nlpfam, the Nlpfam gene can be effectively interfered after the dsRNA or the interference reagent is injected into the brown planthopper, the abdomen of the brown planthopper becomes black, and the brown planthopper death can be inhibited. The brown planthopper can be effectively killed, and the biological control on the brown planthopper is realized.

The invention discloses a site for stably expressing protein in a CHO cell gene NW023276806.1 and application of the site, and belongs to the technical field of biological genes. The site belongs to a fixed position in a CHO cell genome, different protein genes are introduced based on a micro-homologous end connection mechanism through a CRISPR / Cas9 tool, and stable expression is carried out. By adopting a site-specific integration method, a target gene is integrated to a stable expression area in a site-specific manner, repeated high-expression monoclonal screening is effectively avoided, and an MMEJ mechanism is introduced to integrate a donor fragment, so that the research and development time for constructing a stable expression cell strain in biological pharmacy can be effectively shortened, and the cost is reduced.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.

The invention relates to the technical field of protein purification, in particular to a biological method for purifying fusion protein through two different affinity tags. Two affinity purification tags and a dissolution promoting tag are perfectly combined, so that soluble expression of recombinant protein is ensured, high-purity target protein can be obtained through a two-step mild and efficient affinity purification process, the function and activity of the protein are ensured, a complex'capture-medium purification-fine purification 'multi-step purification process is avoided, and the method is suitable for industrial production. The purification process is shortened, the purification time is shortened, the purification efficiency is improved, and the method can be used for production and purification of functional proteins.

The invention belongs to the field of gene engineering, and relates to a gene-deleted recombinant toxoplasma gondii strain vaccine and a construction method thereof, in particular to a gene-deleted recombinant toxoplasma gondii strain, a drug and / or a biological product containing the gene-deleted recombinant toxoplasma gondii strain, a construction method and application of the gene-deleted recombinant toxoplasma gondii strain. The toxoplasmosis vaccine with attenuated activity developed based on the recombinant toxoplasmosis strain is suitable for immunoprophylaxis of toxoplasmosis of various mammals, can block transmission of toxoplasmosis to people and other animals, and is especially suitable for immunoprophylaxis of cat toxoplasmosis infection and / or toxoplasmosis. The vaccine is easy to produce, high in safety, excellent in efficacy, long in immunization duration, capable of distinguishing vaccine immunization from natural infection, free of pollution to animals and the environment, capable of effectively reducing residues of toxoplasma oocysts in the environment and reducing the risk that people are infected with toxoplasmosis, and has huge application potential and important public health significance.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The present invention provides a method for packaging a BaEV retroviral vector. The method includes constructing a stable BaEV retroviral packaging cell line, transfecting a retroviral vector plasmid containing a target sequence into a virus-producing cell line, where the virus-producing cell line is a HEK293T cell line or its derivative cell line, to harvest the transiently transfected and virus-producing retroviral vector, mixing it with the stable BaEV retroviral packaging cell line, and promoting the transduction of the retroviral vector into the stable BaEV retroviral packaging cell line by horizontal centrifugation. The present invention can achieve the packaging of a BAEV-type retroviral vector carrying a CD19CAR foreign gene plasmid, construct a BAEV-type retroviral vector-producing cell line, and produce a high-titer BAEV-type retroviral vector.

The invention provides a composition of probiotics, a preparation method and application of the composition in promoting sleep, the composition comprises probiotics and active peptide for promoting sleep, the amino acid sequence of the active peptide is shown as SEQ ID NO: 1, and the probiotics are selected from lactobacillus and bifidobacterium. The composition can effectively improve the sleep condition, regulate neurotransmitter secretion, improve the immunity of the organism and maintain the stability of the internal environment.

The invention relates to the field of gene engineering, and particularly discloses a barnacle chitin antibacterial peptide, an engineering algal strain of the barnacle chitin antibacterial peptide and a preparation method and application of the engineering algal strain. Wherein the amino acid sequence of the barnacle chitin antibacterial peptide is as shown in SEQ ID NO. 1; or an amino acid sequence which is obtained by substitution and / or deletion and / or addition of one or more amino acids of SEQ ID NO.1 and has the same function as SEQ ID NO.1; or an amino acid sequence which has 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology with the SEQ ID NO.1 and has the same function as the SEQ ID NO.1. The brand-new barnacle chitin antibacterial peptide obtained in the application has a good antibacterial effect, bacteria can be killed through a cell protection barrier, and the cell hemolysis rate at the minimum inhibition concentration is 7.2%.

The invention discloses tetrapeptide KA4 with an anti-fatigue function as well as a preparation method and application of the tetrapeptide KA4, and belongs to the technical field of biology. The tetrapeptide KA4 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is KYPA, and the tetrapeptide KA4 has strong binding capacity with KEAP1, AMPK and LDH, can significantly reduce the serum lactic acid content of a fatigue model mouse and significantly increase the load swimming time of the fatigue model mouse, has an anti-fatigue function, and can be applied to development of functional food for relieving fatigue.

The disclosure relates to compositions and methods for altering, e.g., enhancing, the level of frataxin protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful in the treatment of subjects who have, have been diagnosed with having, or are at risk of having a disorder associated with frataxin (FXN) deficiency, e.g., Friedreich's Ataxia.

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to enhance production yield and fruit quality of cucumber by selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and, at early growth stage, applied to the soil around and / or leaf surface of the cucumber plants. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, before administering as taught herein.

The invention provides conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof, and belongs to the technical field of biological medicine. The invention provides an anticoagulant polypeptide Cb-13. The amino acid sequence of the anticoagulant polypeptide Cb-13 comprises SEQ ID No.1. The invention also provides a coding gene of the anticoagulant polypeptide Cb-13, and provides that the anticoagulant polypeptide Cb-13 does not have hemolytic activity and does not have cytotoxicity when the concentration is 400 [mu] M or below. The anticoagulant polypeptide Cb-13 disclosed by the invention has a prolonging effect on plasma recalcification and coagulation time, has an anticoagulant effect, has small influence on bleeding, and also has an obvious promoting effect on plasmin and uPa. Meanwhile, it is also proved that the anticoagulant polypeptide Cb-13 can inhibit thrombus formation, that is, the anticoagulant polypeptide Cb-13 has in-vivo and in-vitro fibrinolytic effect and anticoagulant effect, has small bleeding risk, and can be used as an antithrombotic or thrombolytic drug.

Provided herein are methods and compositions for expressing Otoferlin, e.g., utilizing adeno-associated viral (AAV) particles. Further provided herein are compositions of AAV particles comprising one or more polynucleotides encoding Otoferlin are codon optimized for expression in human cells. Such methods and compositions may be useful for treatment of diseases and disorders such as Deafness, Autosomal Recessive 9 (DFNB9). Also provided are kits comprising such compositions.

The invention relates to a stable silk fibroin liquid condensation body, gel and a preparation method and application thereof, and belongs to the technical field of silk fibroin. The preparation method comprises the following steps: S1, dissolving silk fibroin in a lithium bromide solution, and then adding trypsin for incubation to obtain an enzyme-digested silk fibroin solution; and S2, performing low-temperature programmed centrifugal treatment including an induction stage, a nucleation stage and a liquid-liquid phase separation stage on the enzyme-digested silk fibroin solution, and cleaning to obtain the stable silk fibroin liquid-state aggregate, the method can reduce aggregate liquid drop aggregation and improve the particle size uniformity of the liquid drops.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The invention provides a recombinant keratin polypeptide as well as a preparation method and application thereof, and relates to the technical field of genetic engineering. The amino acid sequence of the recombinant keratin polypeptide is as shown in any one of SEQ ID No. 1, SEQ ID No. 4, SEQ ID No. 7 and SEQ ID No. 10. The recombinant keratin polypeptide has a good soothing effect and the effects of stimulating skin angiogenesis and improving local blood circulation, and can be widely applied to the industries of medicines, cosmetics, skin care products and the like.